ReviewCells2023
Blood-Derived Lipid and Metabolite Biomarkers in Cardiovascular Research from Clinical Studies: A Recent Update.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Causal Links Between the Plasma Lipidome and Cognitive Performance: Targets, Pathways, and Lifestyle Influences.Molecular neurobiology · 2026Article
- Serum metabolic fingerprinting for diagnosis and therapeutic applications of ovarian endometriosis.iScience · 2026Article
- Diagnostic Potential of Metabolomic and Proteomic Biomarkers in Cardiology-A Narrative Review.Biomedicines · 2026Review
- The ratio of circulatory levels of sphingolipids to steroids predicts asthma exacerbations.Nature communications · 2026Article
- Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics.Briefings in bioinformatics · 2026Article
- Identification of plasma phosphatidylethanolamine species associated with myocardial infarction risk in patients with stable angina: A cross-sectional lipidomics study.The Journal of international medical research · 2025Article
- Association of Apolipoprotein E polymorphism with lipoprotein metabolism and cardiovascular disease risk in rheumatoid arthritis patients.Clinical rheumatology · 2025Article
- Impact of myocardial revascularization surgery on the plasma metabolome.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- The one-key-to-two-doors role of lipidomics: plasma lipidome, cardiovascular risk and statin usage.Journal of lipid research · 2025Article
- Rhodotorula Yeast Culture Improved the Antioxidant Capacity, Lipid Metabolism, and Immunity of Sheep Livers.Veterinary sciences · 2025Article
- A LASSO-derived model for the prediction of nonattainment of target LDL-C reduction with PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease.Lipids in health and disease · 2025Article
- Metabolic perturbations in cardiomyopathies: implications for early diagnosis and targeted interventions.Frontiers in cardiovascular medicine · 2025Review
- Nuclear Magnetic Resonance (NMR)-Based Lipidomics Reveal the Association of Altered Red Blood Cell (RBC) Membrane Lipidome with the Presence and the Severity of Coronary Artery Stenosis.Molecules (Basel, Switzerland) · 2024Article
- Lipid metabolism disorders and albuminuria risk: insights from National Health and Nutrition Examination Survey 2001-2018 and Mendelian randomization analyses.Renal failure · 2024Article
- [Correlation of serum ferredoxin 1 and lipoic acid levels with severity of coronary artery disease].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary prevention, early detection, and treatment of cardiovascular disease (CVD) have been long-standing scientific research goals worldwide. In the past decades, traditional blood lipid profiles have been routinely used in clinical practice to estimate the risk of CVDs such as atherosclerotic cardiovascular disease (ASCVD) and as treatment targets for the primary prevention of adverse cardiac events. These blood lipid panel tests often fail to fully predict all CVD risks and thus need to be improved. A comprehensive analysis of molecular species of lipids and metabolites (defined as lipidomics and metabolomics, respectively) can provide molecular insights into the pathophysiology of the disease and could serve as diagnostic and prognostic indicators of disease. Mass spectrometry (MS) and nuclear magnetic resonance (NMR)-based lipidomics and metabolomics analysis have been increasingly used to study the metabolic changes that occur during CVD pathogenesis. In this review, we provide an overview of various MS-based platforms and approaches that are commonly used in lipidomics and metabolomics workflows. This review summarizes the lipids and metabolites in human plasma/serum that have recently (from 2018 to December 2022) been identified as promising CVD biomarkers. In addition, this review describes the potential pathophysiological mechanisms associated with candidate CVD biomarkers. Future studies focused on these potential biomarkers and pathways will provide mechanistic clues of CVD pathogenesis and thus help with the risk assessment, diagnosis, and treatment of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.